Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.
It has been suggested that lipoatrophy associated with exposure to nucleoside analogues is caused by depletion of mitochondrial DNA (mtDNA). The aim of the present study was to determine whether switching treatment from a thymidine analogue to abacavir was associated with an increase in the mtDNA copy number in peripheral blood mononuclear cells (PBMCs). Of 111 patients with lipoatrophy who were randomized to have treatment switched to abacavir or to continue treatment with thymidine analogues, 94 patients had PBMCs obtained at baseline and at weeks 4, 12, and 24, for quantification of the mtDNA copy number. During the 24-week study, there was no significant change in mtDNA copy numbers in PBMCs in either treatment group, despite improvement in peripheral lipoatrophy among patients whose treatment was switched to abacavir.
Infectious Diseases Unit, Alfred Hospital, Melbourne,Victoria, Australia. jennifer.hoy@med.monash.edu.au
Jennifer F
JF
Hoy
Michelle E
ME
Gahan
Andrew
A
Carr
Don
D
Smith
Sharon R
SR
Lewin
Steve
S
Wesselingh
David A
DA
Cooper
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004272:DNA, Mitochondrial / Q000097:blood*; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D000099227:Abacavir
D019380:Anti-HIV Agents; D004272:DNA, Mitochondrial; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir